Valuation: Tarsus Pharmaceuticals, Inc.

Market Cap 255.18Cr 223.81Cr 207.29Cr 190.73Cr 360.76Cr 24TCr 367.78Cr 2.47TCr 969Cr 12TCr 958.21Cr 937.26Cr 41TCr P/E 2026 *
-51.5x
P/E 2027 * 19.9x
Enterprise Value 255.18Cr 223.81Cr 207.29Cr 190.73Cr 360.76Cr 24TCr 367.78Cr 2.47TCr 969Cr 12TCr 958.21Cr 937.26Cr 41TCr EV / Sales 2026 *
3.64x
EV / Sales 2027 * 2.82x
Free-Float
96.94%
Yield 2026 *
-
Yield 2027 * -
1 day+2.01%
1 week-11.54%
Current month-5.77%
1 month-4.26%
3 months-18.36%
6 months-21.68%
Current year-27.56%
1 week 56.96
Extreme 56.96
70.68
1 month 56.51
Extreme 56.51
72.5
Current year 56
Extreme 56
83.92
1 year 38.51
Extreme 38.51
85.25
3 years 12.57
Extreme 12.57
85.25
5 years 10.8
Extreme 10.8001
85.25
10 years 10.8
Extreme 10.8001
85.25
Manager TitleAgeSince
Chief Executive Officer 48 01/09/2018
Director of Finance/CFO 64 24/04/2023
Chief Tech/Sci/R&D Officer 47 04/11/2024
Director TitleAgeSince
Chairman 48 02/12/2022
Director/Board Member 71 01/12/2019
Director/Board Member 80 01/01/2017
Date Insider Type Main position Quantity % Market Cap.
25/06Free

Director

7,060 0.0164%
25/06Free

Director

6,254 0.0145%
25/06Free

Director

6,254 0.0145%
Change 5-day change 1-year change 3-year change Capi.($)
+2.01%-11.54%+51.38%+238.33% 255.18Cr
-0.22%+2.04%+16.79%-8.03% 6.75TCr
-1.02%-8.04%+35.27%+194.25% 5.11TCr
+0.36%+40.00%+40.00%+40.00% 4.34TCr
+1.34%-0.81%-49.11%-52.89% 4.03TCr
+4.96%+0.27%+55.75%-24.80% 3.09TCr
-1.85%-18.08%+99.20%-47.07% 2.66TCr
-2.12%-1.20%+66.54%+84.42% 2.28TCr
+1.07%+3.27%+9.82%+177.50% 1.98TCr
-0.78%-4.46%+55.18%+125.37% 1.65TCr
Average +0.77%-4.42%+38.08%+72.71% 3.21TCr
Weighted average by Cap. +0.56%-3.12%+30.50%+46.95%

Financials

2026 *2027 *
Net sales 70Cr 61Cr 57Cr 52Cr 99Cr 6.71TCr 101.06Cr 678.86Cr 266.25Cr 3.3TCr 263.29Cr 257.53Cr 11TCr 91Cr 79Cr 74Cr 68Cr 128.14Cr 8.68TCr 130.64Cr 877.58Cr 344.19Cr 4.26TCr 340.36Cr 332.92Cr 15TCr
Net income -5.56Cr -4.87Cr -4.51Cr -4.15Cr -7.86Cr -531.87Cr -8.01Cr -54Cr -21Cr -261.19Cr -21Cr -20Cr -902.01Cr 15Cr 13Cr 12Cr 11Cr 21Cr 1.46TCr 22Cr 147.19Cr 58Cr 714.52Cr 57Cr 56Cr 2.47TCr
Net Debt - -
Logo Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company's lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. It is investigating the development of its product candidates to address targeted diseases with medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction. It is also developing IRX-101, an investigational ocular antiseptic.
Employees
370
Date Price Change Volume
13/26/13 $59.31 +2.01% 11,13,250
10/26/10 $58.14 -9.35% 23,67,158
09/26/09 $64.14 -5.30% 21,68,792
08/26/08 $67.73 -4.00% 13,30,643
07/26/07 $70.55 +5.22% 16,85,124
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
59.31USD
Average target price
94.56USD
Spread / Average Target
+59.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TARS Stock